US FDA approves higher-dose of Biogen's genetic disorder drug
30/03/2026 12:34
March 30 (Reuters) - The U.S. Food and Drug Administration has approved a higher-dose version of Biogen's BIIB.O drug for a rare genetic disorder that causes progressive muscle weakness, offering patients a potentially more effective option, the company said on Monday. (Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Biogen
See all newsHealth Rounds: Old cancer drug may help restore fertility for certain women
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout